JP4658461B2 - キノン系肝疾患治療剤 - Google Patents
キノン系肝疾患治療剤 Download PDFInfo
- Publication number
- JP4658461B2 JP4658461B2 JP2003298700A JP2003298700A JP4658461B2 JP 4658461 B2 JP4658461 B2 JP 4658461B2 JP 2003298700 A JP2003298700 A JP 2003298700A JP 2003298700 A JP2003298700 A JP 2003298700A JP 4658461 B2 JP4658461 B2 JP 4658461B2
- Authority
- JP
- Japan
- Prior art keywords
- liver cancer
- recurrence
- treatment
- menatetrenone
- dcp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000019423 liver disease Diseases 0.000 title description 14
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 title 2
- 201000007270 liver cancer Diseases 0.000 claims description 45
- 208000014018 liver neoplasm Diseases 0.000 claims description 45
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 31
- 235000009491 menaquinone-4 Nutrition 0.000 claims description 30
- 239000011676 menaquinone-4 Substances 0.000 claims description 30
- 229960005481 menatetrenone Drugs 0.000 claims description 30
- 108010063628 acarboxyprothrombin Proteins 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 12
- 238000004393 prognosis Methods 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 5
- 206010064390 Tumour invasion Diseases 0.000 claims description 4
- 230000009400 cancer invasion Effects 0.000 claims description 4
- 210000003240 portal vein Anatomy 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229930003448 Vitamin K Natural products 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- PXKSAXUKRMRORY-ZWKOTPCHSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2r)-2-(2,5-dihydropyrrol-1-yl)cyclohexyl]-n-methylacetamide Chemical compound N1([C@@H]2CCCC[C@@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CC=CC1 PXKSAXUKRMRORY-ZWKOTPCHSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- -1 absorption promoters Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101100074988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nmp-1 gene Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Description
Koike Y. Cancer 2001;91:561-9 Cancer 1992;69:31-8 Hepatology 1995;22:876-82
また、上記目的は、PVIの発生抑制剤製造のためのメナテトレノンの使用により達成される。
以下に本発明の実施例を挙げるが、これらは例示的なものであって、本発明はこれらの実施例に限定されるものではない。当業者は、以下に示す実施例のみならず本願明細書にかかる特許請求の範囲に様々な変更を加えて実施することが可能であり、かかる変更も本願特許請求の範囲に包含される。
以下のようにして、臨床試験(Randomized Prospective Controlled Study)を行った。
実施例2
VK−IIによる肝細胞癌の治療後再発の抑制効果と安全性を検討する目的で、以下の試験を行った。
即ち、1999年3月から2001年3月に、肝細胞癌と診断され、且つ、その治療後に造影CTにて完全に壊死(または治癒切除)と判断された症例(61例)をエントリーし、エントリー症例を、患者ID番号末尾が奇数をVK−II投与群、偶数を非投与群(対照群)の2群に分け、投与群にはVK−II製剤(商品名グラケー;エーザイ株式会社製)を45mg/日の投与量にて経口投与した。3ヵ月毎に造影CTまたはMRIを行い、再発までの期間を統計的に解析した。即ち、Kaplan−Meier法(Logrank検定)で比較し、再発の危険のある割合(Risk Ratio)をCox比例ハザードモデルで解析した。
図6は、肝癌再発抑制(50%再発)に対するVK−II投与の効果確認試験において、HCV症例に限った場合の結果を示したグラフである。図6に示すように、50%再発までの期間は、VK−II投与群で26ヶ月であったのに対し、対照群では10ヶ月であった。
Claims (4)
- メナテトレノンを有効成分として含み、Des-γ-Carboxy Prothrombin(DCP)陽性肝癌治療後の予後を改善するための、肝癌治療・予防剤。
- 門脈内腫瘍浸潤(PVI)の発生抑制剤である請求項1記載の剤。
- メナテトレノンを有効成分として含むDCP陽性肝癌治療後の生存率改善剤。
- メナテトレノンを有効成分として含む、DCP陽性肝癌治療後の肝癌の再発抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003298700A JP4658461B2 (ja) | 2002-08-26 | 2003-08-22 | キノン系肝疾患治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002245178 | 2002-08-26 | ||
JP2003298700A JP4658461B2 (ja) | 2002-08-26 | 2003-08-22 | キノン系肝疾患治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004107330A JP2004107330A (ja) | 2004-04-08 |
JP4658461B2 true JP4658461B2 (ja) | 2011-03-23 |
Family
ID=32301177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003298700A Expired - Lifetime JP4658461B2 (ja) | 2002-08-26 | 2003-08-22 | キノン系肝疾患治療剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4658461B2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004093858A1 (ja) * | 2003-04-23 | 2006-07-13 | エーザイ株式会社 | Mmp発現抑制剤 |
WO2006080463A1 (ja) * | 2005-01-28 | 2006-08-03 | Fukuoka University | ビタミンkヒドロキノン誘導体を用いる癌治療剤および再発予防剤 |
JP5103608B2 (ja) * | 2006-02-10 | 2012-12-19 | 国立大学法人名古屋大学 | 肝癌治療又は予防用医薬組成物 |
JP7174370B2 (ja) * | 2018-10-22 | 2022-11-17 | 正剛 阿比留 | 予後改善剤 |
-
2003
- 2003-08-22 JP JP2003298700A patent/JP4658461B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2004107330A (ja) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110494166A (zh) | 组合疗法 | |
Heath et al. | Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors | |
Choulis | Miscellaneous drugs, materials, medical devices, and techniques | |
JP4658461B2 (ja) | キノン系肝疾患治療剤 | |
JP7278405B2 (ja) | 小細胞肺がんの治療におけるキアウラニブの使用 | |
Eadie | Phenytoin | |
JP6283054B2 (ja) | 生体内のメイラード反応抑制剤またはAGEs生成抑制剤 | |
AU2003277184B2 (en) | Quinone-type remedy for liver disease | |
US7138433B2 (en) | Quinone-based therapeutic agent for hepatopathy | |
AU2003285351B2 (en) | Agent having a destructive effect on malignant tumors and method for the production thereof | |
JP2004067513A (ja) | キノン系肝疾患治療剤 | |
JP6894516B2 (ja) | 血管遮断剤として有用なベンゾフェノンチアゾール誘導体およびトポイソメラーゼ抑制剤を含む癌の予防または治療用薬学的調合物 | |
JP2020519576A (ja) | 肝細胞癌の治療 | |
JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
CN114728003A (zh) | 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 | |
WO2019146129A1 (ja) | イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用 | |
RU2292875C2 (ru) | Хиноновое терапевтическое средство для лечения заболевания печени | |
RU2784869C1 (ru) | Чиаураниб для лечения мелкоклеточного рака легкого | |
WO2005065671A1 (ja) | キノン系化合物を有効成分とする肝癌の発癌予防剤 | |
EP4285907A1 (en) | Drug composition for treating pediatric cancers | |
EP4274562A1 (en) | Treatment regimens with fixed doses of tamibarotene | |
Nakajima et al. | SAT-437 Influence of Smoking on Thyroid Function in Japanese Subjects: Longitudinal Study for One Year of On-Off Smoking | |
Nagasaka et al. | Effect of Fusaric Acid (a dopamine β‐hydroxylase inhibitor) on Phaeochromocytoma | |
Maxwell et al. | Differentiated thyroid carcinoma | |
WO2022146970A1 (en) | Methods of metabolizing metopimazine and its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040213 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060228 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140107 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4658461 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |